Global Fibrinogen Market Growth 2023-2029

Global Fibrinogen Market Growth 2023-2029

Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
LPI (LP Information)' newest research report, the “Fibrinogen Industry Forecast” looks at past sales and reviews total world Fibrinogen sales in 2022, providing a comprehensive analysis by region and market sector of projected Fibrinogen sales for 2023 through 2029. With Fibrinogen sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Fibrinogen industry.
This Insight Report provides a comprehensive analysis of the global Fibrinogen landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Fibrinogen portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Fibrinogen market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Fibrinogen and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Fibrinogen.
The global Fibrinogen market size is projected to grow from US$ 779.3 million in 2022 to US$ 2185.4 million in 2029; it is expected to grow at a CAGR of 2185.4 from 2023 to 2029.
Global core fibrinogen manufacturers include CSL Behring, LFB Group and Shanghai RAAS Blood Products etc. The top 1 companies hold a share about 52%. North America is the largest market, with a share about 31%, followed by Europe and Asia Pacific with the share about 28% and 26%.
This report presents a comprehensive overview, market shares, and growth opportunities of Fibrinogen market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Human Fibrinogen
Animal Fibrinogen
Segmentation by application
Congenital Fibrinogen Deficiency
Surgical Procedures
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL Behring
LFB Group
Shanghai RAAS Blood Products
Jiangxi Boya Bio-Pharmaceutical
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
GREEN CROSS
Shanghai XinXing Medical
Taibang Biologic
Octapharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Fibrinogen market?
What factors are driving Fibrinogen market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Fibrinogen market opportunities vary by end market size?
How does Fibrinogen break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.